pl-100 and HIV-Infections

pl-100 has been researched along with HIV-Infections* in 1 studies

Reviews

1 review(s) available for pl-100 and HIV-Infections

Article	Year
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Our structure-based design strategies which specifically target the HIV-1 protease backbone, resulted in a number of exceedingly potent nonpeptidyl inhibitors. One of these inhibitors, darunavir (TMC114), contains a privileged, structure-based designed high-affinity P2 ligand, 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF). Darunavir has recently been approved for the treatment of HIV/AIDS patients harboring multidrug-resistant HIV-1 variants that do not respond to previously existing HAART regimens. Topics: Clinical Trials as Topic; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Structure; Structure-Activity Relationship; Sulfonamides	2007

Article

Year

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

Our structure-based design strategies which specifically target the HIV-1 protease backbone, resulted in a number of exceedingly potent nonpeptidyl inhibitors. One of these inhibitors, darunavir (TMC114), contains a privileged, structure-based designed high-affinity P2 ligand, 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF). Darunavir has recently been approved for the treatment of HIV/AIDS patients harboring multidrug-resistant HIV-1 variants that do not respond to previously existing HAART regimens.

Topics: Clinical Trials as Topic; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Structure; Structure-Activity Relationship; Sulfonamides

2007